Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022
Poster presentation details:
Poster Title: | VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models |
Publication Number: | 2650 |
Presenter: | |
Session Type: | In-Person and e-Poster Presentation |
Session |
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II |
Session Date and Time: | |
Location: |
Poster presentation details:
Poster Title: | Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor: Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) |
Publication Number: | 4256 |
Presenter: | |
Session Type: | In-Person and e-Poster Presentation |
Session |
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III |
Session Date and Time: | |
Location: |
Poster presentation details:
Poster Title: | Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma |
Publication Number: | 4793 |
Presenter: | |
Session Type: | In-Person and e-Poster Presentation |
Session |
802. Chemical Biology and Experimental Therapeutics: Poster III |
Session Date and Time: | |
Location: |
A copy of the presentation materials can be accessed on the Investors section of the Company’s website at www.vincerx.com once the presentation has concluded.
About Vincerx Pharma, Inc.
Contacts
646-889-1200
bmackle@lifesciadvisors.com
Source: Vincerx Pharma, Inc.